Most Recent
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.
The Australian Competition and Consumer Commission has dropped its claims of collusion against rail freight companies Pacific National and Aurizon, as the trial in its competition case wraps up this week.
The court overseeing the ACCC's collusion case against rail freight operators Aurizon and Pacific National has granted a confidentiality request by BlueScope Steel over documents subpoenaed after the steel company told the court trucks were not a viable alternative for transporting its goods in Queensland.
Two barristers suing DLA Piper over $370,000 in fees did not perform all the work for which they billed the law firm, a court heard Monday.
A judge has ordered auto components distributor Frontline Australasia to pay $1.1 million in damages after reproducing wire harnesses made by Lumen Australia without permission and supplying the unauthorised parts to car makers Mazda and Mitsubishi.
A Queens Counsel and a junior barrister at the Victorian Bar are taking DLA Piper to court, accusing the law firm of failing to pay more than $370,000 in fees.
The Australian Securities & Investments Commission has largely prevailed on appeal to the High Court in its case against former directors of collapsed retirement village owner Prime Trust, including former federal health minister Michael Wooldridge.
Pacific National would not misuse its market power after taking control of an important rail terminal in Brisbane because that would be "irrational", the Federal Court heard Monday at the start of a two-week trial in the competition watchdog's case alleging the rail giant colluded with competitor Aurizon to become the dominant operator of key freight corridors.
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.
Wyeth must pay a group of generic drug companies for the harm they suffered after the drug maker won interlocutory injunctions blocking their plans to market an extended release generic version of anti-depressant Effexor, in a ruling likely to have a chilling effect on interlocutory injunction grants in pharmaceutical patent cases.